Neuren Pharmaceuticals is likely to build on its near-40 per cent share price jump this week after an update on its Phase 2 clinical trial of its NNZ-2591 candidate in Angelman syndrome (AS).
There are currently no approved medicines for AS, which is characterized by severe developmental delay and learning disabilities that become noticeable by the age of 6 – 12 months. Neuren says the last subject to be screened this week will complete the enrolment of subjects into the trial with results expected in third quarter of next year.
Neuren's share price rocketed to a record on Monday when it announced positive results from its Phase 2 clinical trial of its NNZ-2591 drug in children with Phelan-McDermid syndrome, which also has no specific medications, drugs, or therapies. The most common characteristics are moderate to severe developmental and intellectual impairment and developmental delay.
Shares last at $23.96, up 39.8 per cent since its $17.14 close on Friday.